Pratt KP - Search Results

1

Dangerous liaisons: how the immune system deals with factor VIII.

Wroblewska A, Reipert BM, Pratt KP, Voorberg J. Wroblewska A, et al. Among authors: pratt kp. J Thromb Haemost. 2013 Jan;11(1):47-55. doi: 10.1111/jth.12065. J Thromb Haemost. 2013. PMID: 23140211 Free article. Review.

2

Tolerating Factor VIII: Recent Progress.

Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Lacroix-Desmazes S, et al. Among authors: pratt kp. Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019. Front Immunol. 2020. PMID: 31998296 Free PMC article. Review.

3

T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

James EA, van Haren SD, Ettinger RA, Fijnvandraat K, Liberman JA, Kwok WW, Voorberg J, Pratt KP. James EA, et al. Among authors: pratt kp. J Thromb Haemost. 2011 Apr;9(4):689-99. doi: 10.1111/j.1538-7836.2011.04202.x. J Thromb Haemost. 2011. PMID: 21251204 Free PMC article.

4

T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.

James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. James EA, et al. Among authors: pratt kp. J Thromb Haemost. 2007 Dec;5(12):2399-407. doi: 10.1111/j.1538-7836.2007.02762.x. J Thromb Haemost. 2007. PMID: 18034765 Free article.

5

Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.

Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW. Pratt KP, et al. Thromb Haemost. 2004 Sep;92(3):522-8. doi: 10.1160/TH03-12-0755. Thromb Haemost. 2004. PMID: 15351848

6

B-cell and T-cell epitopes in anti-factor VIII immune responses.

Pratt KP, Thompson AR. Pratt KP, et al. Clin Rev Allergy Immunol. 2009 Oct;37(2):80-95. doi: 10.1007/s12016-009-8120-7. Clin Rev Allergy Immunol. 2009. PMID: 19184559 Review.

7

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.

Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE; PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Pandey GS, et al. Nat Med. 2013 Oct;19(10):1318-24. doi: 10.1038/nm.3270. Epub 2013 Sep 15. Nat Med. 2013. PMID: 24037092 Free PMC article.

8

Inhibitory antibodies in hemophilia A.

Pratt KP. Pratt KP. Curr Opin Hematol. 2012 Sep;19(5):399-405. doi: 10.1097/MOH.0b013e328356ed37. Curr Opin Hematol. 2012. PMID: 22814650 Review.

9

Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Kim YC, Zhang AH, Su Y, Rieder SA, Rossi RJ, Ettinger RA, Pratt KP, Shevach EM, Scott DW. Kim YC, et al. Among authors: pratt kp. Blood. 2015 Feb 12;125(7):1107-15. doi: 10.1182/blood-2014-04-566786. Epub 2014 Dec 10. Blood. 2015. PMID: 25498909 Free PMC article.

10

Progress toward inducing immunologic tolerance to factor VIII.

Scott DW, Pratt KP, Miao CH. Scott DW, et al. Among authors: pratt kp. Blood. 2013 May 30;121(22):4449-56. doi: 10.1182/blood-2013-01-478669. Epub 2013 Mar 15. Blood. 2013. PMID: 23502223 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page